EEF1A2 and ovarian carcinoma: Additionally, in late-stage ovarian cancer, particularly in cases of serous endometrium cancer, the amplification of the 20q13 locus and EEF1A2 copy number further underscore its potential as a biomarker for assessing patient survivability [3].